Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Debt (2023 - 2025)

Historic Non-Current Debt for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2025 value amounting to $219.5 million.

  • Xeris Biopharma Holdings' Non-Current Debt changed N/A to $219.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.5 million, marking a year-over-year change of. This contributed to the annual value of $217.0 million for FY2024, which is 1365.62% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Non-Current Debt is $219.5 million.
  • In the past 5 years, Xeris Biopharma Holdings' Non-Current Debt registered a high of $219.5 million during Q3 2025, and its lowest value of $190.9 million during Q4 2023.
  • Moreover, its 3-year median value for Non-Current Debt was $217.8 million (2025), whereas its average is $212.8 million.
  • Examining YoY changes over the last 5 years, Xeris Biopharma Holdings' Non-Current Debt showed a top increase of 1365.62% in 2024 and a maximum decrease of 1365.62% in 2024.
  • Over the past 3 years, Xeris Biopharma Holdings' Non-Current Debt (Quarter) stood at $190.9 million in 2023, then rose by 13.66% to $217.0 million in 2024, then rose by 1.13% to $219.5 million in 2025.
  • Its Non-Current Debt was $219.5 million in Q3 2025, compared to $218.6 million in Q2 2025 and $217.8 million in Q1 2025.